Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332813 · ClinicalTrials.gov registry record · Phase 1
Reducing HIV Risk Among Pregnant Women in Drug Treatment
A Phase 1 study, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT00332813: Completed Phase 1 study, sponsored by Rhode Island Hospital.
NCT00332813 is a Phase 1 study that has completed, run by Rhode Island Hospital. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332813, a Phase 1 study, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
We propose to develop and pilot test an intervention that addresses both sex- and drug-related HIV risk behavior among pregnant women in drug treatment. In the first phase of the study, we will conduct focus groups with pregnant women in drug treatment, as well as a focus group with their treatment providers, in order to determine key areas of emphasis for an intervention in this population. We will then develop an HIV risk behavior intervention for pregnant women in drug treatment, pilot the intervention with 20 women, and elicit their feedback regarding the intervention. Following refinement of the intervention, we will conduct a small randomized trial (n=60) to examine the impact of the intervention compared to standard care (SC). We expect that, relative to SC, participants randomized to the intervention condition will have lower levels of sex- and drug-related HIV risk behavior.
Interventions
- BEHAVIORAL HIV Risk Behavior Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
What the finished NCT00332813 record still lists
NCT00332813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 1 intervention - of which HIV Risk Behavior Intervention is the first listed.
NCT00332813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00332813 about?
NCT00332813 is a clinical study titled "Reducing HIV Risk Among Pregnant Women in Drug Treatment". We propose to develop and pilot test an intervention that addresses both sex- and drug-related HIV risk behavior among pregnant women in drug treatment. In the first phase of the study, we will conduct focus groups with pregnant women in drug treatment, as well as a focus group with their treatment ...
What is the current status of trial NCT00332813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2006-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00332813?
The interventions under investigation include: HIV Risk Behavior Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00332813?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00332813's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia